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INTRODUCTION
Asthma is an airway disorder characterized by inflammation, 
variable airflow obstruction, and airway hyperresponsiveness 
(AHR). The infiltration of eosinophils, mast cells, and CD4 lym-
phocytes, in addition to airway remodeling (including subepi-
thelial fibrosis and hyperplasia of goblet cells and smooth mus-
cle fibers), are all characteristic of asthma.
1 Excessive produc-
tion of interleukin (IL)-4, -5, and -13 by T helper type 2 (Th2) 
cells has been implicated in the pathogenesis of allergic asth-
ma. IL-5 mobilizes eosinophils from the bone marrow pool 
while chemokines such as eotaxin-1 induce the recruitment of 
eosinophils to the airway.
2 Eosinophils are multifunctional leu-
kocytes that release a plethora of immunomodulatory com-
pounds, including potent inducers of the inflammatory and 
immune responses observed in asthma, eczema, rhinitis, and 
other autoimmune diseases.
3 Airway eosinophils, which re-
lease mediators that damage the airway epithelium, have been 
thoughted as a major contributor to AHR in asthmatic patients 
4; however, this paradigm has been challenged by data obtained 
from studies in humans. In one such study, the administration 
of an anti-IL-5 antibody decreased peripheral blood and spu-
tum eosinophilia in asthmatic patients but did not affect airway 
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hyperreactivity.
5 Subsequent analysis of bronchial biopsies 
confirmed these findings and highlighted the role of eosino-
phils in airway tissue remodeling.
6 Thus, while much has in-
deed been learned about the role of eosinophils in asthma, 
many unanswered questions remain. In this manuscript, I shall 
first describe the results of studies performed in my laboratory 
and discuss the biological and morphological differences be-
tween asthma and eosinophilic bronchitis (EB). EB is an inter-
esting clinical manifestation of eosinophilic airway disease that 
does not involve AHR, demonstrating that airway eosinophilia 
alone is insufficient to merit a diagnosis of asthma. Second, I 
will describe and discuss the effect(s) of single-nucleotide poly-
morphisms (SNPs) in the genes CCR3, IL-5 RECEPTOR ALPHA 
(IL5RA), and IL1RL1, and the in vitro and in vivo effects of 
Notch inhibition on both eosinophil differentiation and experi-
mental asthma. 
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While much has indeed been learned about the biology and role of eosinophils, the paradigm of eosinophils has the pros and cons in development 
of asthma. To answer the questions in the black box, this review firstly discusses the biological and morphological differences between asthma and 
eosinophilic bronchitis (EB). EB is an interesting clinical manifestation of eosinophilic airway disease that does not involve airway hyperresponsive-
ness (AHR), demonstrating that airway eosinophilia alone is insufficient to merit a diagnosis of asthma. Secondly, I will describe and discuss the 
effect(s) of single-nucleotide polymorphisms (SNPs) in the genes CCR3, IL-5 RECEPTOR ALPHA (IL5RA), and IL1RL1, and finally the in vitro and in vivo 
effects of Notch inhibition on both eosinophil differentiation and experimental asthma. Eosinophilic airway inflammation is not as important in the 
pathogenesis and maintenance of asthma as had previously been thought. However, the role of eosinophils in other asthma subphenotypes, includ-
ing refractory or severely remodeled asthma, needs to be evaluated further. High-throughput methodologies such as genomics will facilitate the dis-
covery of new markers of inflammation; these, in turn, will aid in the evaluation of the role of eosinophils in asthma and its various subphenotypes.
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LESSONS FROM A CLINICAL PHENOTYPE OF 
EOSINOPHILIC BRONCHITIS
There exists a poorly defined group of patients with similar 
levels of eosinophilic airway inflammation but normal airflow 
and no evidence of BHR.
7 EB is a common cause of chronic 
cough syndrome.
8,9 Morphologic and cellular changes, includ-
ing alterations in basement membrane thickness and in the 
numbers of eosinophils, mast cells, and T-lymphocytes in the 
submucosa, are comparable in EB and asthma. In addition, no 
differences in the expression of eosinophil-active cytokines, 
chemokines, T-cell activation markers, or exhaled nitric oxide 
have been found among individuals with these conditions.
10,11 
However, in our study using thin-section CT scanning, those 
patients with EB showed no thickening of the large airway 
walls, whereas the amount of trapped air and centrilobular 
prominence were similar in patients with EB and asthma (Fig. 
1).
12 These results suggest that eosinophilic inflammation is not 
always accompanied by large airway wall thickening, which 
may explain the normal responsiveness to methacholine in the 
airways of EB patients. The absence of BHR in EB is also attrib-
uted to the normal number of mast cells in airway smooth 
muscle as compared to asthma.
13 The infiltration of airway 
smooth muscle by IL-4- and IL-13-expressing mast cells is 
characteristic of asthma but not EB.
14 This was confirmed by as-
says of the IL-13 level in sputum samples. IL-13 was present at 
higher concentrations in the sputum of asthmatics as com-
pared to those with EB; IL-5 levels were similar between the 
two groups (Fig. 2). In addition, sputum IL-13 levels were in-
versely correlated with the PC20 concentration in subjects with 
asthma.
15 These findings raise the possibility that interactions 
between mast cells and airway smooth muscle in addition to 
the overproduction of cytokines contribute to bronchial wall 
thickening and the development of AHR, but that eosinophils 
do not. However, in a long-term prospective follow-up study,
16 
EB recurred in one-fifth of patients who stopped using inhaled 
steroids. A progressive reduction in FEV1 was observed in indi-
viduals with recurrent EB, but not in those whose EB was non-
recurrent (Fig. 3). This suggests that recurrent EB is accompa-
nied by deterioration of the airflow rate. Based on these find-
ings, it is possible that some subjects with recurrent EB also 
have a component of asthma or chronic asthmatic bronchitis; 
thus, further research is needed.
ASSOCIATION OF GENETIC VARIANTS WITH BLOOD 
EOSINOPHILIA
Prior to the publication of a genome-wide association study, 
research on candidate genes provided information on the con-
tribution of eosinophilia-associated genetic alterations to asth-
ma. Eosinophilic infiltration and peripheral blood eosinophilia 
are dependent on the cooperative action of eosinophil-specific 
cytokines and chemokines (e.g., IL-5 and members of the eo-
taxin family). CCR3, an eotaxin receptor, plays an important 
role in the infiltration of eosinophils into target tissues in coop-
eration with IL-5.
2 The human CCR3 gene (MIM number 
601268), located on chromosome 3p21.3, has been linked to 
atopic dermatitis and asthma.
17 IL-5 is important for the termi-
nal differentiation, activation, and survival of committed eo-
sinophil precursors, via an effect mediated by IL-5 receptor (IL-
5R).
18 The human IL-5R complex is a heterodimer composed of 
alpha and beta subunits.
19 The IL5RA gene (MIM number 
147850), located on chromosome 3p26-p25, has also been 
linked to the development of asthma.
20 In a genome-wide scan 
using polymorphic markers, the linkage of chromosome 5q 
with familial eosinophilia was shown.
21 This region contains a 
Fig. 1.  Comparison of the (A) percentage of wall area (WA%), (B) prominence of centrilobular structures, and (C) air trapping on HRCT scans between patients with 
eosinophilic bronchitis (EB), mild asthma, and normal controls. The WA% was comparable in patients with EB than in normal controls (A). The prominence of centri-
lobular structures (B) and airway trapping (C) were comparable in patients with EB and mild asthma.
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cytokine gene cluster that includes three genes, the products of 
which play important roles in the development and prolifera-
tion of eosinophils: IL3, IL5, and CSF2. However, no other stud-
ies have demonstrated sporadic eosinophilia-associated genet-
ic variants in this region. We previously reported the associa-
tion of variations in candidate genes with eosinophilia in asth-
ma. Three completely linked SNPs (222557G>A, 2520T>G, and 
2174C>T) in CCR3 as well as the c.25091G>A polymorphism 
and c.2480_482ins/del in IL5RA were associated with eosino-
phil abundance in the peripheral blood of asthmatics.
22 There is 
an intergenetic association between CCR3 ht2 and c.25091G>A 
of IL5RA, such that the genetic effect of this combination low-
ers P values more than the effect of either condition alone (Ta-
ble 1). 
Data from a genome-wide SNP study of 9,392 Icelanders with 
known blood eosinophil counts suggested that an SNP (rs-
1420101) in IL1RL1 was associated with asthma; a similar phe-
nomenon was observed in a collection of ten different popula-
tions (7,996 cases, including 1,958 Koreans and 44,890 controls; 
Table 2).
23 SNPs within the genes encoding WDR36, IL-33, and 
MYB that showed a suggestive association with eosinophil 
counts were also associated with atopic asthma in these popu-
lations. Rs1420101 on 2q12 is located in IL1RL1, while rs3939286 
on 9p24 is located 32 kb proximal to the start codon of IL-33. IL-
33 encodes a cytokine belonging to the IL1 superfamily, and is 
the natural ligand for the IL1RL1 receptor. IL-33 also functions 
as a chromatin-associated nuclear factor with transcriptional 
regulatory properties.
24 Signaling through the IL1RL1-IL-33 
Fig. 3.  Time-dependent changes in the FEV1 of patients with non-recurrent 
(solid line) and recurrent (dashed line) eosinophilic bronchitis (EB). FEV1 was 
significantly lower in the latter group compared with the former during months 
9 and 12 of the study period. The data are presented as mean values + SEM. 
*P=0.01 compared to the group with nonrecurrent EB.
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Fig. 2.  IL-13 (A) and -5 (B) levels in the induced-sputum of asthmatic patients (BA), those with eosinophilic bronchitis (EB), and healthy control subjects (NC). Open 
and closed symbols represent atopic and non-atopic subjects, respectively. Horizontal bars represent the median values for each of the three groups. (C) Correlation 
between sputum IL-13 levels and the PC20 for methacholine in the asthmatic patients. There was a significant, inverse correlation between the IL-13 level and PC20 
for methacholine (r=0.484; P=0.02).
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complex has an important role in eosinophil maturation, sur-
vival, and activation, both by direct effects on eosinophils and 
indirectly through the recruitment and regulation of Th2 cell ef-
fector functions. These findings are consistent with the pro-
posed function of IL1RL1-IL-33 signaling in eosinophil-medi-
ated inflammation.
25 After functional analysis reveals how these 
genetic variances affect the differentiation of eosinophils and 
development of asthma, they may be used as targets for novel 
diagnostic assays and therapies.  
Table 1. Association of the IL5RA c.25091G>A genotype and CCR3 ht2 with the peripheral blood eosinophil count in asthmatic patients
22
IL5RA c.25091 G > A
GG GA or AA P value
†
N GM* (95% CI) N GM* (95% CI)
CCR3 ht2 +/+ 6 213.7 (82.1-556.6) 10 181.7 (113.5-290.7) 0.643
-/+ 58 270 (223.1-327.6) 30 314.6 (240.8-411.1) 0.426
-/- 150 318.4 (273.3-371.0) 92 444.9 (378.8-522.6) 0.003
P value
‡ Cod 0.444 0.001
Dom 0.344 0.002
Rec 0.283 0.002
*Values are presented as geometric means.
†The P values for the association of IL5RA c.25091G>A were obtained using a general linear model type III SS, controlling for age and sex as covariables.
‡The P values for the association of CCR3 ht2 were obtained using a general linear model type III SS, controlling for age and sex as covariables.
Cod, codominant model; Dom, dominant model; Rec, recessive model.
Table 2. Results of a genome-wide search for SNPs associated with peripheral blood eosinophil counts and replication
23 
SNP Chr. Position Freq. Gene
Icelandic 
discovery
(n=9,392)
Icelandic
follow-up
(n=4,458)
Other European
(n=7,660)
Combined
European
(n=21,510)
East Asian
(n=5,212)
Effect P Effect P Effect P
Effect
(95% CI)
P Freq Effect P
SNPs satisfying the criteria for genome-wide significance             
rs1420101[A] 2 102,324,148 0.41 IL1RL1 6.4 2.2×10
-6 10.6 8.5×10
-11 4.4 0.0064 6.4
(4.7, 8.1) 
5.3×10
-14 0.37 4.8 0.046
rs12619285[G] 2 213,532,290 0.74 IKZF2 6.8 5.1×10
-6 4.1 0.024 7.0  7.6×10
-5 6.3
(4.3, 8.3) 
5.4×10
-10 0.36 5.9 0.017
rs4857855[T] 3 129,743,240 0.82 GATA2 8.3 1.5×10
-6 9.6 3.6×10
-6 11.0  1.3×10
-7 9.4
(7.2, 11.6) 
8.6×10
-17 0.70  8.4 0.00057
rs4143832[C] 5 131,890,876 0.16 IL5 10 4.6×10
-8 12.3 1.0×10
-8 2.0  0.34 7.1
(4.9, 9.2) 
1.2×10
-10 0.17 10.2 0.0039
rs3184504[T] 12 110,368,991 0.38 SH2B3 7.7 1.3×10
-8 10.6 8.5×10
-11 6.6 3.2×10
-5 7.6
(5.9, 9.3) 
6.5×10
-19 0.00    
SNPs that did not satisfy the criteria for genome-wide significance 
rs2416257[G] 5 110,463,389 0.85 WDR36 7.9 2.5×10
-5 6.1 0.0070  4.4 0.062 6.1
(3.7, 8.6) 
1.0×10
-6 0.95 -4.4 0.27
rs2269426[T] 6 32,184,477 0.76 MHC 6.0  1.9×10
-5 5.1 0.0023 1.5 0.48 4.6
(2.7, 6.6) 
2.9×10
-6 0.30  -0.4 0.89
rs9494145[T] 6 135,474,245 0.33 MYB 7.4 1.5×10
-6 6.6 0.00037 -0.9 0.66 4.3
(2.4, 6.2) 
1.2×10
-5 0.70  2.5 0.38
rs748065[A] 8 21,734,049 0.69 GFRA2 6.0  2.9×10
-5 2.7 0.11 1.6 0.36 3.8
(1.8, 5.7) 
0.00012 0.43 -0.5 0.84
rs3939286[A] 9 6,200,099 0.25 IL33 6.8 8.2×10
-6 2.8 0.13 2.7 0.14 4.4
(2.4, 6.5) 
1.8×10
-5 0.03 -1.9 0.72Park
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REGULATION OF EOSINOPHIL DIFFERENTIATION AND 
NOTCH SIGNALING
During eosinophil development, the early action of IL-3 and 
GM-CSF results in the proliferation and differentiation of stem 
cells into multipotent myeloid and eosinophil progenitor cells, 
while IL-5 supports the expansion, terminal differentiation, 
and functional activation of eosinophils. Notch is an evolution-
arily conserved transmembrane protein involved in the regula-
tion of a broad spectrum of cell fate decisions and differentia-
tions.
26 Notch signaling regulates the terminal differentiation 
and subsequent effector phenotypes of eosinophils, partly 
through modulation of the ERK pathway.
27 Enzymatic cleavage 
of Notch by γ-secretase is essential for Notch-mediated signal-
ing. Gamma-secretase inhibitor (GSI) has been used to effec-
tively block Notch signaling; the pharmacological equivalent of 
a loss of Notch function. We previously demonstrated that GSI 
induces the differentiation of eosinophils lacking effector func-
tions.
28 Notch signaling is also required for the development of 
Th2-type immunity.
29 It is, therefore, possible that the restric-
tion of Th2 and eosinophil inflammatory responses by GSI will 
ameliorate the symptoms of asthma. GSI administration has 
been shown to inhibit many of the pathological and histologi-
cal characteristics of asthma, including eosinophilic airway in-
flammation, goblet cell metaplasia, methacholine-induced 
AHR, and elevated serum IgE levels (Fig. 4A and B).
30 An ex vivo 
study of the effect of GSI on stimulated BAL cells showed both 
the inhibition of Th2 cytokine production and the augmenta-
tion of Th1 cytokine production (Fig. 4C). This skewing of the 
cytokine production profile from Th2- to Th1-type responses 
provides an empirical basis for the use of GSI as an antiasthma 
agent. Notch has been shown to directly induce the transcrip-
Fig. 4.  Therapeutic effects of g-secretase inhibitor (GSI) administration on air-
way inflammation in ovalbumin (OVA)-induced mice.
30 (A) Inhibition of inflam-
matory cell infiltration by GSI. Bronchoalveolar lavage fluid (BALF) was collect-
ed 48 hr after the final OVA challenge. Total and differential cell counts were 
performed by enumerating a minimum of 300 cells. The data represent the 
mean + SEM; n=18 per group. (B) Airway hyperresponsiveness (AHR) was as-
sessed as airway resistance in mice (n=8-10 per group) treated with GSI (0.3, 
0.03 or 0.003 mg/kg) after challenge with increasing concentrations of aero-
solized methacholine; *P<0.05 and **P<0.01, compared with the OVA-chal-
lenged group. Dimethyl sulfoxide (DMSO; 2% v/v) was used in combination 
with OVA. (C) Effect of incubation time and GSI dose on cytokine production by 
BAL cells. BAL cells were collected from the airways of mice sensitized and 
challenged with OVA. Cells were stimulated with PMA (P) and ionomycin (I) in 
the presence of varying concentrations of GSI for the indicated time periods. 
The results are expressed as the mean values of triplicate determinations (se-
lected as representative from a total of three to five independent experiments) 
+ SEM.
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tion of GATA-3.
31 Reduced GATA-3 levels in BAL cells due to GSI 
treatment cause decreased Th2 cytokine production via a 
Notch-dependent pathway, thereby inhibiting Th2-associated 
responses in the airway. GSI treatment also increases T-bet lev-
els, which promote a Th1 response, as evidenced by enhanced 
IFN-γ expression. The marked effect of GSI on eosinophil dif-
ferentiation and the balance of Th1- and Th2-type responses 
mediated by Notch-dependent signaling demonstrate the po-
tential therapeutic value of this protein in the treatment of asth-
ma. 
In summary, the data presented herein suggest that eosino-
philic airway inflammation is not as important in the patho-
genesis and maintenance of asthma as had previously been 
thought. However, the role of eosinophils in other asthma sub-
phenotypes, including refractory or severely remodeled asth-
ma, needs to be evaluated further. High-throughput methodol-
ogies such as genomics and proteomics will facilitate the dis-
covery of new markers of inflammation; these, in turn, will aid 
in the evaluation of the role of eosinophils in asthma and its 
various subphenotypes. Biomarkers detected as important in 
airway eosinophilia will help highlight processes involved in 
the pathogenesis of subphenotypes of asthma, including the 
possible participation of eosinophils.
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